

ASCO 2005

Zoledronic acid (ZOMETA): a Significant Improvement in the Treatment of Bone Metastases

Zsuzsanna NAGY

Department of Clinical Oncology, St Imre Hospital, Budapest, Hungary

Bone metastases are frequent complications of breast, lung and prostate cancers, multiplex myeloma, and less frequently of other neoplasms, causing pain, pathological fractures, hypercalcemia, spinal cord compressions.¹ These symptoms have a major impact on the quality of life and should be controlled by appropriate therapy. Bisphosphonates became an essential element in the treatment of bone metastases. These pyrophosphate analogues target and inhibit osteoclast activity,² and in the past 15 years were included in many clinical trials.

Newer N-containing bisphosphonates (e.g. zoledronate, pamidronate, ibandronate) inhibit the mevalonate pathway of cholesterol biosynthesis *in vitro*, and interfere with protein prenylation in osteoclasts *in vivo* by inhibiting farnesyl diphosphate synthase. Prenylation is an important posttranslational modification of small guanosine triphosphate-binding proteins (as Ras, Rho, Rac) which have many important regulatory functions.

It was proved that members of bisphosphonate family (as clodronate, pamidronate) could reduce the incidence and severity of skeletal complications (skeletal-related events, SREs).^{3,4} Further improvement has been achieved by zoledronic acid which in comparative studies with other bisphosphonates was more convenient to use and was also more effective, further decreasing the skeletal-related events.^{5,6} Recently, the effect of zoledronic acid (4 mg, 15 min infusion, every 4 weeks for 1 year) has been studied in 227 Japanese women with bone metastases (mainly osteolytic lesions) from breast cancer.⁷ Besides decreasing the pain (median pain score), the study showed a significant 39% reduction in the rate of SREs in patients treated with zoledronic acid compared with placebo.

There are increasing evidences that newer aminobisphosphonates, especially zoledronic acid, have direct anti-

tumor activity.⁸ Several clinical trials support that bisphosphonates can increase the survival when used in adjuvant setting. In a randomized, multicenter trial clodronate (1600 mg/day) significantly reduced the risk of bone metastasis, and there was also an improvement in overall survival with long term follow-up.⁹ In another study with oral clodronate, overall survival improved in breast cancer patients with micrometastases.¹⁰ The Adjuvant Zoledronic acid to Reduce Recurrence (AZURE) trial is under evaluation, targeting the effect of zoledronic acid on disease-free survival and incidence of bone metastases in patients given standard adjuvant treatment.¹¹

Cessation of estrogen production increases the risk of bone loss in postmenopausal women with breast cancer. Therefore it is understandable that aromatase inhibitors can even increase the bone resorption marker levels and accelerate the bone loss. In a recent clinical trial (Z-FAST trial, 6-month study assessment) the lumbar spine and total hip bone marrow density increased in patients (postmenopausal women with early breast cancer) receiving letrozole and upfront zoledronic acid.¹² The evaluation at 12 months reflected the same results.¹³

Many of the above mentioned results created positive echo at the ASCO Annual Meeting (2005). Botteman et al¹⁴ found that zoledronic acid appears to be the most cost effective i.v. bisphosphonate therapy compared to generic pamidronate and ibandronate, or to no therapy. In a phase III trial advanced breast carcinoma patients with at least one confirmed osteolytic or mixed bone lesion received either oral ibandronate (50 mg/day) or i.v. zoledronic acid (4 mg, 15 min infusion, every 4 weeks for 12 weeks).¹⁵ When markers of bone resorption were compared, oral ibandronate seemed to be as effective as i.v. zoledronic acid. The primary endpoint was the change of cross-linked C-terminal telopeptide of type I collagen in serum (S-CTX). Using another marker of bone resorption (urinary N-telopeptide) Lipton et al claimed that in breast cancer and multiple myeloma the normalization of the elevated level of this marker after 3 months of treatment with zoledronic acid

Received: June 10, 2005; accepted: June 23, 2005

Correspondence: Zsuzsanna NAGY, MD, Department Clinical Oncology, St Imre Hospital, Tétényi u. 12-16, Budapest, H-1115, Hungary. Tel./fax: +36 1 4648732

is a good predictor of favorable outcome measured by skeletal-related events and time to first SRE.¹⁶ Adjuvant pamidronate therapy also showed significantly reduced development of bone metastases in perimenopausal women with primary breast cancer according to a survey on 429 patients with primary operable stage I-III breast cancer.¹⁷

There are still many open questions in the use of bisphosphonates.¹⁸ How can we identify patients responding or not responding to these therapy? What is the reason of the resistance against bisphosphonates and how can we overcome this problem? Is there any useful effect of bisphosphonates in the management of primary breast cancer when added to standard anticancer therapy? Solving these and other similar problems requires a joint effort and sponsorship of many agencies, including pharmaceutical industry, governmental sources or different foundations.

References

1. Coleman RE: Metastatic bone disease: clinical features, pathophysiology and treatment strategies. *Cancer Treat Rev* 27: 165-176, 2001
2. Russell RG, Rogers MJ: Bisphosphonates: From the laboratory to the clinic and back again. *Bone* 25: 97-106, 1999
3. Hurst M, Noble S: Clodronate: A review of its use in breast cancer. *Drugs Aging* 15: 143-167, 1999
4. Theriault RL, Lipton A, Hortobagyi GN, et al: Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: A randomized, placebo-controlled trial – Protocol 18 Aredia Breast Cancer Study Group. *J Clin Oncol* 17: 846-854, 1999
5. Gordon D, Rosen L, Coleman RE, et al: Long-term efficacy and safety of zoledronic acid compared with pamidronate in treatment of skeletal complications in patients with advanced multiple myeloma of breast cancer, *Proc Am Soc Clin Oncol* 22: 47, 2003 (abstr 188)
6. Perry CM, Figgitt DP: Zoledronic acid: A review of its use in patients with advanced cancer. *Drugs* 64: 1197-1211, 2004
7. Kohno N, Aogi K, Minami H, et al: Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. *J Clin Oncol* 23: 3314-3321, 2005
8. Seneratne SG, Colston KW: Direct effects of bisphosphonates on breast cancer cells. *Breast Cancer Res* 4: 18-23, 2002
9. Powles T, McCloskey E, Kurkilahti M: Oral clodronate for adjuvant treatment of operable breast cancer: results of a randomized, double-blind, placebo-controlled multicenter trial. *Proc Am Soc Clin Oncol* 23: 9, 2004 (abstr 528)
10. Jaschke A, Bastert G, Solomayer EF, et al: Adjuvant clodronate treatment improves the overall survival of primary breast cancer patients with micrometastases to bone marrow – a longtime follow-up. *Proc Am Soc Clin Oncol* 23: 9, 2004 (abstr 529)
11. Coleman R, Gralow J, Bell R, Lipton A: Zoledronic acid is being investigated for the prevention of bone metastases in patients with early stage cancer. 7th workshop on Bisphosphonates, 24-26 March 2004, Davos, Switzerland (abstr 60)
12. Brufsky A, Harker GW, Beck J, et al: Zoledronic acid for prevention of cancer treatment induced bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: preliminary results of the Z-FAST trial. 27th Annual San Antonio Breast Cancer Symposium 2004, San Antonio (abstr 1114)
13. Brufsky A, Harker W, Beck J, et al: Zoledronic acid (ZA) effectively inhibits cancer treatment-induced bone loss (CTIBL) in postmenopausal women (PMW) with early breast cancer (BCa) receiving adjuvant Letrozole (Let): 12 mos BMD results of the FAST trial. *ASCO Annual Meeting, Orlando, 2005* (abstr 533)
14. Botteman MF, Aapro MS, Hay JW, et al: Cost effectiveness of intravenous (IV) zoledronic acid vs other IV bisphosphonates for the prevention of bone complications in breast cancer patients with bone metastases: A Markov model from the UK perspective. *ASCO Annual Meeting, Orlando, 2005* (abstr 721)
15. Body J, Lichinitser M, Tjulandin S, et al: Effect of oral ibandronate versus intravenous (i.v.) zoledronic acid on markers of bone resorption with breast cancer and bone metastases: Results from a comparative phase III trial. *ASCO Annual Meeting, Orlando, 2005* (abstr 534)
16. Lipton A, Hei Y, Coleman R, et al: Suppression of bone turnover markers by zoledronic acid and correlation with clinical outcome. *ASCO Annual Meeting, Orlando, 2005* (abstr 532)
17. Jung J, Hwang G, Lee Y, et al: Pamidronate as adjuvant treatment for prevention of bone metastasis in breast cancer. *ASCO Annual Meeting, Orlando, 2005* (abstr 888)
18. Hortobagyi GN: Progress in the management of bone metastases: One continent at a time? *J Clin Oncol* 23, 1-3, 2005